Stay updated with breaking news from Trappsol Cyclo. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Cyclo Therapeutics (NASDAQ:CYTH – Get Rating) is one of 41 publicly-traded companies in the “Industrial organic chemicals” industry, but how does it compare to its peers? We will compare Cyclo Therapeutics to similar companies based on the strength of its dividends, institutional ownership, profitability, earnings, risk, valuation and analyst recommendations. Institutional & Insider Ownership 5.2% […]
Cyclo Therapeutics (NASDAQ:CYTH – Get Rating) is one of 41 publicly-traded companies in the “Industrial organic chemicals” industry, but how does it weigh in compared to its rivals? We will compare Cyclo Therapeutics to similar companies based on the strength of its institutional ownership, dividends, profitability, analyst recommendations, risk, earnings and valuation. Insider & Institutional […]
Cyclo Therapeutics, Inc. (NASDAQ:CYTH – Get Rating) was the recipient of a large increase in short interest during the month of March. As of March 31st, there was short interest totalling 64,000 shares, an increase of 257.5% from the March 15th total of 17,900 shares. Based on an average daily trading volume, of 65,800 shares, […]
Cyclo Therapeutics (NASDAQ:CYTH – Get Rating) is one of 42 publicly-traded companies in the “Industrial organic chemicals” industry, but how does it compare to its peers? We will compare Cyclo Therapeutics to related companies based on the strength of its valuation, earnings, risk, dividends, analyst recommendations, institutional ownership and profitability. Volatility & Risk Cyclo Therapeutics […]
Cyclo Therapeutics (NASDAQ:CYTH – Get Rating) is one of 42 public companies in the “Industrial organic chemicals” industry, but how does it weigh in compared to its competitors? We will compare Cyclo Therapeutics to similar businesses based on the strength of its analyst recommendations, institutional ownership, valuation, profitability, dividends, risk and earnings. Analyst Recommendations This […]